Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.08.009 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Paul Dobry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA; Department of Pharmacy Practice, Wayne State University, Detroit, Michig…. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Atrial Fibrillation, Venous Thromboembolism, Hemorrhage. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
BACKGROUND: A paucity of data exists to support the use of factor (F)Xa inhibitors in severely obese patients with a weight of ≥150 kg or body mass index (BMI) of ≥50 kg/m2. OBJECTIVES: The purpose of this study was to evaluate whether FXa inhibitors are as safe and effective as warfarin for the treatment of atrial fibrillation (AF) and/or venous thromboembolism (VTE) in individuals with a BMI of ≥50 kg/m2 and/or weight of ≥150 kg. METHODS: This was a multicenter retrospective cohort study of severely obese adult patients with AF and/or VTE treated with a FXa inhibitor or warfarin. The primary effectiveness outcome was composite odds of stroke, systemic embolism, or VTE; the primary safety outcome was odds of major bleeding. Secondary outcomes included incidence of stroke or systemic embolism, VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, change in anticoagulation, and total number of hospital encounters. Outcomes were assessed for 12 months following initiation of study drug. RESULTS: A total of 1736 patients were included. The mean weight and BMI of the overall cohort were 164.4 kg and 54.6 kg/m2, respectively. There was no difference in odds of stroke, systemic embolism or VTE (odds ratio, 1.005; 95% CI, 0.6-1.68), or major bleeding (odds ratio, 0.9; 95% CI, 0.47-1.7) between groups. CONCLUSION: These data suggest that apixaban and rivaroxaban are safe and effective alternatives to warfarin for the treatment of AF and/or VTE in individuals with a BMI of ≥50 kg/m2 and/or weight of ≥150 kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA; Department of Pharmacy Practice, Wayne State University, Detroit, Michigan, USA. Electronic address: paul.dobry@ascension.org.
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA.
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Division of Hospital Medicine, Henry Ford Health, Detroit, Michigan, USA.
- Department of Heart and Vascular Services, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
- Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA; Department of Pharmacy Practice, Wayne State University, Detroit, Michigan, USA.
Zitieren
APA
Dobry, P., Edwin, S. B., Haymart, B., Barnes, G. D., Kaatz, S., Ali, M. A., & Giuliano, C. (2024). Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.08.009
Vancouver
Dobry P, Edwin SB, Haymart B, Barnes GD, Kaatz S, Ali MA, et al. Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.08.009
BibTeX
@article{Dobry2024,
author = {Dobry, Paul and Edwin, Stephanie B and Haymart, Brian and Barnes, Geoffrey D and Kaatz, Scott and Ali, Mona A and Giuliano, Christopher},
title = {Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.08.009}
}
EUVIMED